1:30 PM
 | 
Oct 09, 2018
 |  BC Extra  |  Clinical News

Affimed sinks after placing clinical hold on bispecific T cell engager

Affimed N.V. (NASDAQ:AFMD) fell $1.13 (24%) to $3.50 Tuesday after it placed a clinical hold on two studies of blood cancer candidate AFM11 following three treatment-related serious adverse events, including a patient death. The product is a tetravalent bispecific human antibody targeting CD19 and CD3. Affimed announced the hold late Monday.

AFM is in two Phase I trials to treat relapsed or refractory B cell non-Hodgkin lymphoma...

Read the full 313 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >